In all, these pan-cancer observations offer insights on the classification of patient samples with more vs. less PD-L1 (or CD274) and glycolysis, as well as the worse probability of patient survival linked with their parallel enrichment, which is largely uniform across all evaluated cancer types. Here, CD274 is linked to cancer.